<DOC>
	<DOCNO>NCT02176213</DOCNO>
	<brief_summary>This study do learn drug , pomalidomide gather data safety side effect use combination commercially available cyclophosphamide dexamethasone . This combination consider experimental approved FDA . Pomalidomide third generation immunomodulatory ( IMiDs ) agent , potent version thalidomide lenalidomide drug approve United States Food Drug Administration [ FDA ] treatment MM . In February 2013 , pomalidomide also approve FDA patient MM 2 type therapy . Pomalidomide take orally capsule , cyclophosphamide dexamethasone also take orally tablet study . Cyclophosphamide dexamethasone commercially available often use combination drug treat Multiple Myeloma . Preliminary data laboratory patient study suggest combination drug effective pomalidomide dexamethasone alone . However , regimen use study , consist daily cyclophosphamide , also permit support low blood count either injection transfusion need .</brief_summary>
	<brief_title>Study Pomalidomide , Cyclophosphamide , Dexamethasone Relapsed/Refractory Multiple Myeloma</brief_title>
	<detailed_description>This open label , single center , phase II study combination pomalidomide , daily low dose oral cyclophosphamide , dexamethasone patient relapsed/refractory multiple myeloma . The three oral drug give 28-day cycle : Pomalidomide 4 mg daily x 21 day ; cyclophosphamide 50 mg BID x 21 day ; dexamethasone 40 mg weekly x 3 ( 20 mg weekly patient age ≥ 75 year old ) . Subjects meet eligibility criterion ANC &lt; 1000/µL platelet count &lt; 50,000/µL start dose level -1 pomalidomide ( 3 mg daily ) cyclophosphamide ( 50 mg daily ) . G-CSF platelet transfusion support permit need . Dose reduction hematologic toxicity begin cyclophosphamide subsequently alternate pomalidomide subject tolerate dose level -2 agent - case subject would come study . If subject 2 concurrent toxicity potentially attributable agent ( e.g . hematologic toxicity ) dose modification guideline follow dose reduction do sequentially one agent time , unless opinion investigator , agent require concurrent dose reduction .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Disease relate : Patients must history symptomatic multiple myeloma accord IMWG criterion Patients must receive least two prior line therapy also must refractory lenalidomide . Patient relapse relapsed/refractory MM . Patients must currently measurable disease , define : 1 . Serum Mprotein ≥ 0.5 g/dL 2 . Urine Mprotein ≥ 200 mg/24 hour 3 . Serum free light chain assay : involve FLC level ≥ 10 mg/dl provide serum FLC ratio abnormal 4 . If monoclonal protein detect , &gt; 30 % monoclonal bone marrow plasma cell Demographic : Male female adult ≥ 18 year old Able sign inform consent comply protocol Life expectancy &gt; 12 week ECOG performance status ≤ 2 All study participant must register mandatory POMALYST REMS program , willing able comply requirement POMALYST REMS program . Laboratory ANC ≥ 1000/µL Platelets ≥ 50,000/µL ( Patients plasma cell 50 % bone marrow nucleate cell , platelet ≥ 30,000/µL permitted regardless baseline ANC ) Cr &lt; 3 AST ≤ 2.5 x ULN ALT ≤ 2.5 x ULN Serum Bilirubin ≤ 1.5 x ULN ( except patient Gilbert 's syndrome must total bilirubin &lt; 3 time ULN ) Other Females childbearing potential must negative serum urine pregnancy test sensitivity least 25 mIU/mL within 10 14 day prior within 24 hour start pomalidomide must either commit continued abstinence heterosexual intercourse begin TWO acceptable method birth control least 28 day take pomalidomide . Previous treatment pomalidomide Patients receive chemotherapy radiation therapy 30 % marrowbearing bone within ≤ 2 week experimental agent/therapy within 4 week prior start study treatment ; yet recover side effect therapy Known hypersensitivity thalidomide lenalidomide The development erythema nodosum characterize desquamate rash take thalidomide , lenalidomide similar drug Other concurrent severe and/or uncontrolled medical condition include abnormal laboratory value could cause unacceptable safety risk compromise compliance protocol Patients prophylactic anticoagulation therapy option unless due thrombocytopenia Patients receive allogenic stem cell transplantation &lt; 12 month prior enter study show evidence active graftversushost disease require immunosuppressive therapy Patients exist peripheral neuropathy grade &gt; 2 Patients active malignancy require treatment next 12 month ( except basal squamous cell carcinoma , situ cancer cervix breast , asymptomatic prostate cancer ) Patients known positivity HIV active hepatitis B C Corticosteroid therapies &gt; 20 mg/day prednisone , &gt; 4 mg/day dexamethasone , &gt; 80 mg/day hydrocortisone , equivalent . Oral , inhale , topical steroid allow study long exceed 80 mg/day hydrocortisone .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Pomalidomide</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Dexamethasone</keyword>
</DOC>